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Abstract

The discussion about the economic development of the countries within the Middle East and
North Africa (MENA) region is mostly dominated by the macroeconomic perspectives. The
productivity, innovativeness and international competitiveness of the industries of the MENA
countries have been discussed mainly under the top down approach concluding that the
institutions are the prime facilitators in the development of the industries. When the
institutions do not move in parallel with the needs of the industry, it withers away, becomes
inefficient, gets crippled with lesser chances of growth. Taking a bottom up approach this
paper shows that competitive industry can emerge even where the institutions have not
developed and the available ones are dysfunctional and under-resourced.
JEL classification: I11, I12, I15
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Introduction

The recent social and political events in the MENA region, widely known as Jasmine
Revolution, have drawn significant attentions of different interest groups to get deeper
understanding about the causes and impacts of such event on the development and well-being
of the concerned countries and regions. Previous discussions on the development in the
MENA region countries focused on the dominant cultural attributes in the region and their
relations to social and economic development in the region. Such discussions were sometimes
based on comparison of the development of the MENA region countries with other countries,
mainly the western countries. These analyses worked with standard macroeconomic indicators
and western benchmarking parameters. These analyses mainly ended up with the not so
encouraging prospects of the countries of the region. Absence, inefficiency and voids of the
supporting, monitoring and regulatory institutions were identified as frontrunners among the
key challenges for growth and development of this region. They include dysfunctional
institutions with corruptions (Aysan et al., 2007; Nabil et al., 2007; Nabil, 2007), difficulties
in property rights relating to innovation (Nugent, 2002), general lack of openness to foreign
elements including FDI (Brach, 2008; Brach, 2009) and willingness of the political elites to
maintain status quo. We are mainly concerned in this paper to know that in spite of such
challenges how the region still does some progress. There is a lack in this understanding, as
the extant works are based only on macro-level analyses. A considerable body of meso and
micro-level analysis relating to industrial and economic development in this reason is not
available. In this paper, we focused on analysing the development of one particular industry
based on the general and the particular industry specific institutional perspective of a country.
The purpose is to understand how institutional settings influence the development of an
industry. Development and contribution of some key industries in a country or region are not
reflected in the typical macroeconomic measures of growth and development; whereas
development of such industries are demonstrations of different types of critical competences
which can be exploited for further developments in different sectors
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Taking a bottom-up approach we show that competitive industries can emerge even where the
institutions have not developed and the available ones are dysfunctional and under-resourced.
The cases of Syrian and Bangladesh pharmaceutical industries are both successful stories of
emerging new industries in developing countries. Analysing both, we are faced with these
questions: How could they emerge in such insufficient environments? What have been the
conditions on the micro and on the macro level which first intensified entrepreneurs to invest
into that specific market and how have they learned to be successful? One of the central
point‟s here is the question why the entrepreneurs have been able to take the opportunities
into their business perspective and do not move into rent-seeking behaviour in such
environments?

Though Bangladesh is far from MENA region, we have picked Bangladesh for different
reasons. Bangladesh is a developing country in South-Asia with a good number of cultural
similarities with MENA region countries through their similarity in religious beliefs and
practices. Bangladesh is attributed with challenging institutional setup. In spite of this, a
number of industries like ready-made garments, pharmaceutical and ceramic have
successfully emerged there. We picked Bangladesh in our work to compare Syria with
another country with similar but not same context. Comparing Syrian development with a
western country or with another MENA country could be prone to the limitation of
comparison between very dissimilar or very similar cases.

In the first section of this paper we introduce the theoretical questions, assumptions and their
discussions relating to the emergence of new industries. In the second section we present the
case of the pharmaceutical industries in Syria and Bangladesh. In the third section of this
paper we compare the Syrian and Bangladesh cases to focus on the drivers and trajectories of
the emergence and development of new industries there. We have ended the paper with
comments relating to implications of our work for further research in this issue.
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Theoretical aspects of the emergence of industries - Analysis from the firm’s perspective

The discussion about the emergence of new industries and their dynamics is a crucial point in
the analysis of economic development. Such dynamics such as innovation, competitiveness
and sustainable development have been in the spotlight of the analysis. Taking a bottom-up
approach right from the entrepreneurial perspective, the birth of a single firm can be the initial
point for the emergence of new industries. More deeper analysis of this phenomenon leads to
postulate that entrepreneurs not only kicks off the development of the industry, they also
contribute to the boundary shifting or restructuring the industry (Schumpeter, 1934), as the
emergence of a new firm with a close substitute stands for the shifting of the current boundary
of the industry. Acs et al. (2008) note that dynamics of entrepreneurship can be very different
depending on the availability and the efficiency of the institutions in a particular location and
current level of economic development there. This observation confirms that institutions and
emergence of industry is co-evolutionary (Nelson, 1995). If the whole process of industry
development has to be explained, it looks like a more complex co-evolutionary space
consisted of entrepreneur, institution and technology.

By looking into history and taking a favourable example of economic growth- the first
industrial revolution in Great Britain, Crafts (1996) developed three major implications for
future research in growth economics.

First of all he draws attention to the fact that the major incentive for innovators is the ability
to allocate rents or any form of surplus. He pointed out that undue attention is paid in the
discussion to R&D and learning as well as patenting issues. Secondly the British example
gives us support for the understanding of the role that human-capital formations played in
growth. The capabilities for the transfer of technology and knowledge as well as for
innovation in Britain have been strong and improving at that time. Another example from
Germany during the “Founder Years” shows similar effects. Finally the Industrial Revolution
in Britain shows that the mainstream calls for economic openness as fundamental for growth
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is a paradigm which has to be discussed in detail. The British, German and present-day China
are examples that show growth performance side by side with growing protectionism and
artificial devaluation (see also Elsenhans et al., 2005; Chang, 2002).

Birth of the firm

We want to examine, an outwardly either or looking issue, do the institutions and the
environment kickoff the process of the emergence of an industry or the entrepreneurs do it. If
we conceptualise an industry as a group of firms offering something similar or close substitute
to each other (Porter, 1980), the entrepreneurs kickoff the process. Kirzner (1973) views the
entrepreneur as the entity which looks for opportunities in the market and initiates necessary
actions to exploit the opportunities, and the most recognizable shape of such activities is the
creation of organization (Katz and Gartner, 1988) with high probabilities of survival (Low
and Abrahamson, 1997).

When we go into the theory of Organizational Development and Learning we can find a
simplified example of the steps for the emergence of the firm. Ask the entrepreneur or the key
member of the firm about the starting point for the firm, they will usually answer that in the
beginning there was an idea. But there is still one step before even an idea can originate.
Following the Organizational Development Literature the initial step lies in a strong need. A
potential entrepreneur or a group of them has to come in contact with a need of the
environment. There has to be a problem to solve or a demand to cover or something to
improve. Furthermore the need has to be strong, which means it has to appeal to the potential
entrepreneur, from which he is able to address the need and materialise the idea by
articulating a specific product which has potential for successful commercialisation. From this
a vision emerges within the entrepreneur, such vision motivates and drives the entrepreneur to
organize and invest different forms of resources which may be tangible, intangible or both
(Kofman and Senge, 1995).
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The two crucial points for the success of a company are the capability to seek further needs of
the environment and to attract the resources needed to be invested. Right in the
Schumpeterian scenes the first point is the constant seeking for opportunities to invent, of
which an expected potential surplus return above the costs for the production may arise. An
expected development and imitating of future machinery as well as the costs of maintaining
the learning capabilities and capacities may also be triggered (Elsenhans, 2004). Against the
wisdom that there is minimal economic growth in developing countries because of
insufficient financial resources, which refers to FDI, marginal and underdeveloped economies
are often rather faced with limited investment opportunities because of the absence of markets
for products with mass consumption character (ibid.).

Profit, rent and the perspective of the entrepreneur

Here in our paper, we follow Elsenhans (2001 and 2004) by conceptualizing rent and profit as
two different forms of surplus appropriation. The appropriation of profit is just possible under
the conditions of competition, whereas rent arises in imperfect market conditions and
appropriated through political privileges and power. Rent originates from surpluses under the
conditions of absence of rentable investment possibilities in non-growing markets or in the
absence of pressure for reinvestments in the imperfect market (Alexander 2006). Here the
crucial point is that theoretically every capitalist has to reinvest their profits in the perfect
market condition; otherwise in the long term he will be running out of the market. This also
goes in line with the Schumpeterian assumption for perpetuity of competition as the means of
development through creative destruction (Schumpeter, 1934) under which the entrepreneur
constantly seeks for new innovative investment opportunities.

We do not follow the conceptualisations which perceive rent as any sort of excessive income
(Khan, 2000) in the form of entrepreneurial rent, innovators rent, monopoly rent or others
(Boldrin and Levine, 2003). Those concepts suffer from the challenge that in the short term
perspective forms of rents are the driving forces behind undertaking economic initiatives,
especially for the SMEs, for example profits of the entrepreneurs may appear as rents (Pasour,
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1987). The theoretical conceptualization of rent in neoclassical literature is that rent is the
return in excess of opportunity costs left behind. Opportunity costs are subjective and profits
are made through entrepreneurial activity which makes the objective identification of rents
impossible (ibid.).
Instead of classifying any sort of excessive income we focus more on how different kinds of

surpluses can be appropriated than on how they arise. Strategic decision making and
management of the enterprises has always to deal with uncertainties and the decision maker or
entrepreneur will do anything he can to lower potential risks in the future (Sterman, 1989).
Taking also into account that one of the driving forces for economic activity is that any
entrepreneur tries to reach the best positive rate of surplus he can, or think he can achieve, the
two perspectives of surplus appropriation, rent-seeking and profit seeking, lead to different
behaviours.

Under the business or profit perspective and with the pressure of competition the focus lies on
seeking new innovative product or process development respective adjustments, else the firm
fails in the market. Constantly searching for those strong needs of the environment is
fundamental for long run success of enterprises. Under those conditions the investment of the
available resources has the tendency to be efficient (Elsenhans, 2001).

Under the rent-seeking perspective and with the assumption that rent can just be appropriated
through political privileges the focus lies on attracting that political power to maintain. That
means to invest resources in reaching political goals which not automatically fits with the
needs of the market. The conditions have the tendencies to be inefficient (Krueger, 1974).

Both perspectives can occur in the entrepreneurial decision making at the same time and both
strategies can be successful for the entrepreneur. They are also described above extreme
theoretical stereotypes (ibid.).

Nevertheless in the market it depends on which sort of perspective dominates. If rent
dominates, then, following our assumptions, there is a lack of rental investment opportunities
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and the entrepreneur will invest the available resource to obtain wealth transfers through the
aegis of the state or political powers. Here the probability to gain those transfers depends on
the determination of a small group of people. Their decisions for going for something or
someone are based on non-economic criteria. Non-economic criteria include norms and
culture, which mainly come from private sphere. If the decisions for the wealth transfer
through aegis are not based on economic questions then the uncertainty for the entrepreneur
lies in the “goodwill” or in good relations to the institutions or controller of the resources
(Elsenhans, 1999).

Following the assumption, that long term business success of a firm lies in its capability to
address and fit with the needs of the customers in an ongoing changing environment (Teece et
al., 1997). Only rent-seeking behaviours don‟t guarantee the firms‟ competitiveness in the
market. Rent-based competitiveness can be retained for longer time in the market, when the
market contains significant amount of imperfections. Especially in international market of the
product with greater amount of homogeneity, rent-seeking behaviours don‟t sufficiently
safeguard the competitiveness of the firms. In both the cases of Syria and Bangladesh, the
pharmaceutical industry has demonstrated international competitiveness, even in the western
markets. Their process of internationalisation was fast and they achieved remarkable growth
in international markets. This fact strongly supports the argument of the competitiveness of
the drug production in both countries and hence the arguments that profit perspectives are
dominating.

The cases of the pharmaceutical industries in Syria and Bangladesh

Syria

After the Syrians had ended a period of longstanding political and economic instability in the
beginning of the 1980s, the Syrian government was confronted in the mid 1980s with
financial crisis. The approach to increase and generate growth and employment exclusively
through supporting the state-owned industrial sector failed and the Syrian government was
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pushed to increase the productivity and macroeconomic involvement of the private sector.
(Sukkar, 1994; Perthes, 1992)

For the pharmaceutical sector the Syrian government decided in the end of the 1980s to
support and encourage the domestic private pharmaceutical industry because of the increasing
high import costs for pharmaceutical products which Syria wasn‟t able to pay anymore. (Di
Tomasso et al. 2003) The costs for imported medicine ranged up to 600 million US$ per year
at that time. Only 6 % of the Syrian pharmaceutical demand in 1988 was served by two public
sector companies and 2 % by private sector firms. The balance of the national demand was
imported and distributed by Saydalaya, a state owned company. (Syrian European Business
Centre - SEBC, 2003)

Nevertheless the sponsorship from the Syrian Government was limited. With import
restriction and no effective patent protection through the absence of international intellectual
property rights especially, companies in the pharmaceutical sector had marginal problems to
getting started.

The development of the domestic private pharmaceutical industry in Syria, in the beginning of
the 1990s, was strongly supported by the government through the reinforcement of „Law No.
103 in 1956‟ and the „Law No. 10 in 1991‟. They fostered the private investments in the
Syrian economy. Both Laws encouraged budgetary and regulatory support for the local
producers, export base and development of the local technology. An example of such support
is the provision of the tax waiver for the local producers for three to five years. The Minimum
amount of the capital investment for being eligible for government support under the „Law
No. 10‟ was 10 Million SYP or 217391 US$, which was relatively high in the early 1990s‟
Syrian context. Most of the private owned firms including the pharmaceutical firms were not
in a position, at that time, to comply with this requirement. As a result, quite a few numbers of
the pharmaceutical firms developed at that time. Nevertheless, the introduction of this law and
the reinforcement of „Law No. 103‟ after a period of strict restrictions for the private business
activities encouraged the private entrepreneurs to start-up, which resulted in significant rise in
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the amount of private investments in the industrial sector, including in the pharmaceutical
industry (Wils, 1997; Di Tomasso et al., 2003; SEBC, 2003)

Currently there are 63 pharmaceutical manufacturing units in Syria, which are producing
more than 6500 varieties of medical drugs (SANA, 22 July 2009). Qualities of the products
generally meet the standard criteria, as all of the pharmaceutical production units in Syria are
ISO compliant. The industry provides more than 14,000 jobs, 25 % of them are filled in by
the university graduates and the rate of female employments in this sector is higher than any
other sector of production (SANA, 11 November 2009).1 The turnover in the Syrian domestic
markets reaches to 500 million US$ a year, and the Syrian industry supplies more than 92% of
the human drug needs in the local market. In past 20 years, Syrian pharmaceutical industry
has turned itself around from 90% finished product import to 10% finished product import for
its domestic market.

The Syrian pharmaceutical industry is highly dominated by the private sector. In 2009 the
public sector contributed just 7 % to the Syrian production of pharmaceutical products. Nearly
three quarters of the companies in the pharmaceutical sector are SMEs.

The privately-owned pharmaceutical firms are locally-owned and managed by native Syrians,
as no foreign firm or their subsidiaries are allowed in Syria. Although the Syrian government
is changing the regulatory regime slowly, some sectors like financial sector has been made
open for the foreign firms, but the pharmaceutical sector is reversed for the local private
entrepreneurs only. International engagements in the Syrian pharmaceutical sector are limited
to granting license of the products of the foreign firms to the local Syrian firms and to have
scientific offices in Syria to perform marketing activities for the allowed imports and licensed
products in cooperation with the local Syrian firms. The pricing of the pharmaceutical
products, including domestically produced and imported ones, are controlled by the Ministry
of Health (SEBC, 2003).

1

More than 70 % of the students in pharmacy in Syria universities are female.
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Syrian pharmaceutical industry is ranked second, preceded by Egypt, among the Arab
countries to meet the demands of the local pharmaceutical market by its own production.
With regards to exports in pharmaceutical products, it lies second behind Jordan (SANA, 22
July 2009).

Chart 1. Export performance of the Syrian pharmaceutical industry
120
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Source: Constructed from the data from the Central Bureau of Statistics Syria (2009)

Starting the export activities with the former Soviet Union, Syrian pharmaceutical export has
achieved a tremendous growth in the last years. Chart 1 shows that exports jumped to 19.4
million US$ in 2008 from 1.26 million US $ in 2004. Annual average export growth (in terms
of export value) in this period is around 100 %, while share in the world pharmaceutical trade
increased 75 % per annum in this period. Pharmaceutical industry is the second largest export
industry in Syria, which is just preceded by the mineral oil sector.

Syria is exporting pharmaceutical products to 56 countries all over the world. Most of them
are Arab and African, Asian and South-American. Others are North-American and European
countries including Germany, United Kingdom, Canada, Honduras, Bolivia and Afghanistan.2
Syria is exporting at least 100,000 US$ of pharmaceutical products to at least 21 different
countries, which include Yemen, Sudan, United Arab Emirates, Iraq and Algeria. The exports

2

Central Bureau of Statistic Syria www.cbssyr.org
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to the European Union started to grow and have reached to 1.6 million Euros in 2005 with a
growth rate of 20 % in the period of 2003 and 2005.3

Table 1. Export destination of the Syrian pharmaceutical products
Importing country

Import
(000 US$)

Jordan

1298

United Arab Emirates

1117

Algeria

17831

Sudan

10219

Iraq

89006

Kuwait

14066

Saudi Arabia
Yemen

6882
28472

European Economic Community

473

Germany

666

United Kingdom

78

Bolivia

401

Canada

608

Honduras

3085

Afghanistan

1783

Ghana

64

Source: Central Bureau of Statistics Syria (2009)

Jordan is the biggest exporter of the pharmaceutical products in the region. Syria‟s per capita
in pharmaceutical export is around 3 US$, while that of Jordan is 55 US$. It is ascertained
that if Syria could increase the exports up to the per person level of Jordan the amount of
exports would reach 1.0 billion US$ a year, and the Syrian pharmaceutical industry has the
potential to reach that level (SEBC, 2010).

3

The meanly amount of exports to the European Union compared to other countries in the region like Jordan and
Egypt is based on the fact that until now Syria and the European Union haven‟t signed the free trade
agreement for the Mediterranean region.
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Bangladesh
Bangladesh, a tiny South-Asian nation with a territory of 144000 km2 neighbouring to India,
started out as an independent nation after winning a bloody war of independence against
Pakistan in 1971. In 2007, Bangladesh, with a population size of 153 million, achieved 140th
place (belongs to medium HDI nations group) in the Human Development Index (HDI)
ranking with a HDI score .547 (while in 2007 India scored .619 and Pakistan .551), which
was just .347 in 1970 (UNDP, 2008). This development has drawn applause from the
international press as Perry (2006) in his Times article, comments 'the country now scores
higher than neighbour India on several key parameters of social development, such as infant
mortality, child vaccination, and employment of women, a striking turnaround over the past
decade or so‟.

From the post-colonial to the pre-independence period, i.e. 1948 – 1971, pharmaceutical
market of this region used to be dominated by the imported drugs and the production by the
TNC‟s local subsidiaries, where the role the local firms was both technologically and
commercially insignificant, and this trend continued till the early 1980s (Begum, 2007).
During 1981-1982, 122 companies from 23 countries had been exporting human
pharmaceutical drugs to Bangladesh including 29 UK, 12 USA, 10 Swiss, 9 German and 10
Indian companies (Chowdhury, 1995). In the early 1970s, under a changed world perspective,
featured by the sharp rise of oil price, US departure from Vietnam, nuclear capability
development by India and a strong political role of the „Non-Aligned Movement (NAM)‟,
third world countries attempted to exert more self-control over the determination of their
course of action relating to their economy and welfare, where tackling the increasing cost of
healthcare was an important element on the agenda (Chowdhury, 1996). Among the reasons
of such shamble scenario in the developing countries, pharmaceutical TNC‟s practices had
been alleged and argued to contribute to public health disasters, as reported in the literature
focusing on this issue c.f. marketing drugs with misrepresented therapeutic value (Silverman
et al., 1992), dumping in third world countries (Guha, 1986), few therapeutic value drug
marketing in the third world (Davies, 1994) and unethical profit targeted drug promotion and
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marketing (WHO, 1977). It was a heightened necessity to streamline the pharmaceutical
TNC‟s and the importers‟ detrimental practices and to promote local pharmaceutical industry
development, in order to improve public health situation in the developing countries. In
response to this call, Bangladesh government took initiatives to draw a full-fledged drug
policy suitable to support the healthcare of a developing country like Bangladesh by
constituting an expert committee on April 1, 1982. Recommendations of this expert
committee, after revisions and due process, emerged and had been enforced as the „Drug
Ordinance (Control) 1982‟. The expert committee marked 1742 drugs as non-essential or
therapeutically non-significant and banned their production and distribution under different
implementation frameworks. Among the 1742 drugs, expert committee identified as harmful,
inappropriately formulated or therapeutically ineffective, 176 were being produced by the
TNCs, 617 were being imported and 994 were being produced by 156 local manufacturers.
„DOC (Drug Ordinance Control) 1982‟ initially caused a huge stir among the medical
practitioners, pharmaceutical companies‟ representatives, pharmaceutical TNCs worldwide,
different national governments and the legislative bodies including the US Congress and the
German Bundestag. Bangladesh government finally didn‟t back off from DOC 1982. Later
this initiative was hailed as an example for the other developing nations to follow to fit the
pharmaceutical industry with public health benefits. This legislation was further dubbed as the
turning point of the local pharmaceutical industry development in Bangladesh (Reich, 1994).

The demographic and the economic context got substantially changed over the periods in
Bangladesh. If 1970 -2005 period is considered, the population count stands at 153.3 million
in 2005 from a 79 million of the 1970, though the fertility per woman has dropped down to
3.2 from 6.2 children, infant mortality rate has got reduced to 54/1000 birth from 145/1000
birth and the birth time life expectancy has improved to 62 years from 43.5 years. In 2006, for
this population, there were 1683 hospitals and 51044 hospital beds with 44,632 registered
physicians i.e. one physician for 3125 people (Bangladesh Bureau of Statistics - BBS, 2007).
In the same period, health expenditure from the part of the government was .09% of GDP and
the private contribution was 2%, whereas the per capita health expenditure rose to US $ 64
from the US $ 2 per capita drug expenditure in 1990. These developments along with the
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regulatory reforms served as the driver of the pharmaceutical industry development in
Bangladesh. Pharmaceutical drug market developed from less than € 100 million in 1982 to
more than € 3900 million in 2007.

Local producers are the producers of the generic drugs in their own brand name. There are
237 licensed drug manufacturers in Bangladesh and among them 150 are in operation
(Directorate of Drug Administration Bangladesh - DDA, 2007)4, while 138 are registered
members of the „Bangladesh Association of Pharmaceutical Industries (BAPI, 2007)5, the
apex body of the pharmaceutical drug manufacturers of Bangladesh. This industry employs
65000 skilled people directly and 15000 unskilled people in indirect manner (Lincoln and
Bhattacharjee, 2007). Local producers supply 97% of the yearly domestic demand for the
human pharmaceutical drugs of the country, while the remaining 3% imported finished drug
includes only high-tech therapeutic drugs6 (Faroque, 2006).

There are about 450 generics formulations in Bangladesh with the registration from the DDA.
Among them, 117 are in the controlled category i.e. in the essential drug list. The remaining
333 generics are in the decontrolled category. The total number of the brands /items that are
registered in Bangladesh is currently estimated to be 5,300, while the total number of dosage
forms and strengths is 8,300 (Sarker, 2006).

After consolidating the positions in the domestic market, leading Bangladeshi pharmaceutical
firms tried to explore markets outside Bangladesh. They initially went out to the neighbouring
non-regulated markets e.g. Nepal, Myanmar and Sri Lanka mainly with bulk formulations and
few finished formulations (Begum, 2007). Local firms started to get into export venture
systematically as a serious business option since 1992 (Lincoln and Bhattacharjee, 2007).
Beximco, a leading Bangladeshi manufacturer, exported „Active Pharmaceutical Ingredient
(API)‟ to Hong Kong and later it exported finished formulations there in 1993. In post-1992

4

Professor Habibur Rahman, Director, Drug Administration Bangladesh revealed in a press conference in Dhaka on 11. 04.
2007.
5
Information collected from „Bangladesh Association of Pharmaceutical Industries (BAPI)‟-the apex association of the
owners of the pharmaceutical manufacturing units.
6
Principally vaccines, hormonal drugs and anti-cancer drugs
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period, local drug manufacturers were encouraged by their initial experiences of success in
the neighbouring market as well as by the unfolding of the events in the Soviet Union and
other communist countries. Collapse of the Soviet Union changed the world political
geography and gave birth to the new economies in Central Asia and in Eastern Europe, which
got exposed to serious challenges in the initial periods of their adjustment with the new
system. The newly emerged nations found that their demands for the necessary commodities
including the medical drugs were much higher than their existing supply capabilities, and the
free falling of the purchasing power made this situation even worse. These newly emerged
nations looked for low cost quality sources to fill the gaps, while such suppliers looked
forward to get into these markets as an opportunity for their expansion. Several Bangladeshi
pharmaceutical manufacturers put efforts to get into CIS (Commonwealth of Independent
States - organization of new countries emerged from the breakup of the Soviet Union
including Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia,
Tajikistan, Turkmenistan, and Uzbekistan) countries‟ markets (Begum, 2007).

Beximco was the first to export pharmaceutical drugs to Russia in 1994. Currently, the local
producers are looking onward more to get into international market as a part of their regular
growth and expansion strategies.
Chart 2. Pharmaceutical drugs export from Bangladesh
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Chart 2 shows that pharmaceutical exports from Bangladesh have been significantly
increasing over the years. Though the monetary value of the Bangladesh pharmaceutical
export is quite insignificant in terms of the national export-earning context, it is an important
indicator of export diversification. Export diversification with a knowledge-based and
technology-based product is highly encouraging for a knowledge and technology dearth
country like Bangladesh, as it suggests that the country has received some success in
technology and knowledge capability building which can be extended further. Such export
can be extremely important, as exposure to competition and networks in the export market can
be an important source of learning, capability building, and improvement for the sector
(World Bank, 2008).

Bangladesh pharmaceuticals producers mainly export generic finished formulations in dosage
and bulk form as well as a small amount API (ibid). They mainly export to „moderately
regulated markets‟ i.e. where certification and registration rules are not as stringent as in the
„highly regulated market‟ e.g. USA, Canada, UK, Japan, Germany, France, Italy, and EU, and
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to the „non-regulated markets‟ i.e. where the regulatory requirements are minimum
(Chowdhury, 2006).

Chart 3. Number of the countries importing pharmaceutical drugs from Bangladesh
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Bangladeshi pharmaceutical products are exported to as many as 69 countries of Asia, Africa,
North America, South America, and Europe including Russia, Ukraine, Malaysia, Tanzania,
Vietnam, Philippines, Germany, Sweden, USA, Netherlands and Brazil to name a few. Chart
3 shows the diversification of international markets that Bangladeshi pharmaceutical industry
achieved over the past years.

Insights from Syria and Bangladesh cases
Following the first point of Crafts (1996)‟s historical analysis the major incentive for the
entrepreneurs in Syria and Bangladesh to move into the market of pharmaceutical products
lied in the initial reinforcement of laws, which banned foreign competitors from the respective
domestic markets. In both cases the state decided to cut imports of drugs and to become selfsufficient in that sector because they wanted to reduce negative balance of payments. For the
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local entrepreneurs the new scenario opened up a large market with strong potential demand
for mass consumption. Because of the weakness of the state and the political powers or tribal
structures the market was free for the competition of local manufacturers, where they had to
compete only with local firms from the same starting position for the new vacuum in the
domestic market. The investments for this catch up came from local entrepreneurs which
identified this huge opportunity of a large scale market. Drug production in those cases can be
compared with large scale products for mass consumption. The demand for daily used drugs
was dominating the markets and the production in both cases started with low level generics,
where the knowledge gap as well as the success barriers was relatively small and the cost
manageable.

Beside that in both countries the demand was also backed and subsidized through the public
health system. If mass demand is a precondition for economic growth here the potentials and
incentives had been tremendous.

Taking the second point into account that the available capabilities and human resources in
Great Britain at the time of the Industrial Revolution had been favourable for economic
growth we can argue that a similar effect can be related to the instances in Bangladesh and
Syria.

In both countries there have been no significant barriers for the freedom to operate. The status
of the institutional guaranty for property rights was either absent or significantly low. Hence
the cost for entering the market had been low, especially for manufacturers in the
pharmaceutical sector. North (1995) posits that short run economic growth can occur within
autocratic regimes; in the end the development of the rule of law entails positive long run
economic performance. Here the cases challenge the theoretical discussions of the
neoclassical and institutional economics which require stable and secure property rights as a
precondition for the successful emergence of an industry which is knowledge, technology and
capital intensive like the pharmaceutical sector.
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Here one effect in the Syrian pharmaceutical industry seems to be interesting. There is a
difference between the protection of property rights in the local market and the protection of
international property rights. With regards to international property rights, Syria until now has
not signed the international agreements, which lower the barriers for local activities. In the
case of property rights on the national level the situation improved significantly during the
last decade. This might be one reason why the Global Information Technology Report (GITR)
ranks Syria 61st, preceding Czech Republic, Hungary and Italy (GITR 2010).

Secondly, if capabilities are one of the preconditions for the birth and the success of a firm
and the fast takeover of the market in both cases suggest that the capabilities available were in
the market at the time of take-off, then the question arises: how had the entrepreneurs been
able to learn the needed routines and capabilities?

In case of the development of the pharmaceutical industry in Bangladesh, only two public
universities were offering undergraduate and graduate programs in pharmaceutical science.
The graduates from those universities were working for the TNCs then operating in
Bangladesh. Beside the pharmacists, TNCs were managing their operations in Bangladesh
with local management and support staffs. These pharmacists and managers got exposed to
the production and organizational management practices and standards of the TNCs. These
learning formed the initial phase of the capability development for the pharmaceutical
industry of Bangladesh. Later in the post-1982 (when the Drug Ordinance was enforced),
when TNCs found doing business in Bangladesh not as lucrative as it was before, some of
these people turned out as entrepreneurs in new market condition. Some of them involved not
directly into entrepreneurship but they teamed up with the local entrepreneurs from other
fields to start new pharmaceutical firm. Each of the new entrants in this industry, during initial
phase of the development of Bangladeshi industry, started with the technological and
managerial capabilities of the people who worked previously with TNCs.

Thirdly, even if the national education systems in both countries seem to be insufficient for
the recent growth the potential human resources had been fair enough to start. The further
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development of the education and training of the needed human resources was also mainly
based on private investments.

Table 2. Education scenario in Syria

Arab world
average
Syria
Tunisia

Primary
education

Primary
education
quality

Primary
education
enrolment

Higher
education
and
training

Quality of
education
system

Quality of
management
schools

68.8

Quality
of math
and
science
learning
70.3

73.3

60.9

93.9

68.7

73.8
89.1

50.3
75.6

98.3
101.7

54.5
80.6

54.7
87.9

64.1
90.4

64.4
96.7

79.8

Source: The Arab World Competitiveness Review

In Syria until now the data shows that the institutional framework is still weak whereas the
determinants of education and training as well as foresight and R&D are above the regional
average (Köcker et al., 2009). Hence the level of development of institutions for higher
education as universities and so forth is one of the best capacities in the country (ibid.).
Higher Education in Syria has faced recent changes in the last decade. The opening of this
sector for private activities has generated some sort of gold-digging mentality. Private
universities are growing all over the country. Due the fact that Syria has one of the youngest
population in the area and a tremendous need for academic education, the state universities in
the big cities weren‟t able to meet the demand from the market. Also, following the infamous
tragic incident in the United States on 11th September, 2001, parents increasingly hesitated to
send their children abroad. (Landis, 2007)7

The Global Information Technology Report (GITR) 2010 ranks the availability of scientists
and engineers in Syria positively at 62th, right after Poland. The quality of the education
system in Syria has been ranked at 108th, two positions behind Spain but before Greece,
Mexico and Egypt. The quality of mathematics and science education is ranked 69th before
Israel (94th), which economy is marked as highly innovative. But according to the GITR data
Syria performs poorly in the area of R&D Cooperation between universities and industries.
Syria is ranked here at 136 out of 138. The company spending on R&D is ranked in the same
7

http://www.joshualandis.com/blog/?p=312
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position. Weakness relating to the transfer of knowledge and technology from the higher
education institutions into the economy is also backed by other resources and arrangements
(Köcker et al., 2009). But those data and resources are just general scientific view to the
Syrian reality. Salaries in academic positions in Syria especially at state universities are
poorly paid. Due that fact a high percentage of the academic staff in Syria has a second job to
raise the necessary income resources. Companies which are innovative and investing in R&D
activities have fewer difficulties to find scientific staff without any official cooperation with
universities ore research institutions.8

Table 3. Education scenario in general in Bangladesh
2002

2003

2004

2005

2006

2007

16

15

15

..

14

16

Public spending on education, total (% of GDP)

2

2

2

..

2

3

School enrollment, primary (% net)

..

..

..

87

88

..

School enrollment, secondary (% net)

44

44

41

40

41

41

School enrollment, tertiary (% gross)

5

6

5

6

6

7

Public spending on education, total
(% of government expenditure)

Source: World Bank Database, 2010
Table 3 shows that enrolment in tertiary level is fairly low; where government‟s financial
ability is a significant factor. In spite of that, graduate level pharmacy education started in
1964 in Dhaka. Over the period of time 4 public universities have been giving pharmacy
education, which is not enough to meet the requirements of this growing sector. Since 1994,
14 private universities are offering pharmacy education. The number of qualified pharmacy
science graduates in the country is estimated to be 2527 (Chowdhury, 2008). There are 18
government and 28 private medical colleges in Bangladesh (including 3 dental colleges under
government and 8 under private management) recognized by BMDC (Bangladesh Medical
and Dental Council), where 2120 and 2526 students are enrolled respectively (Director
General Health Services – DGHS Bangladesh, 2008). Beside this, 30 institutes offer postgraduate education and research in health and medical sciences, which include 10 specialized

8

Discussion with the Marketing Director of Atawfeer Solar Water Heater Company during the GIZ Conference
on Prmotion of Innovation in the MENA-Region in January 2011 in Casablanca.
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institutes, 20 specialized hospitals and 10 medical colleges. Post-graduate institutes have 2203
Fellows and 1595 Members (DGHS, 2007). Besides, there are two institutes for training of the
health technology. These institutions are the suppliers of the technical people to the
pharmaceutical industry. Global Information Technology Report (GITR) 2010 of the Global
Economic Forum (GEF) has ranked the quality of the education system of Bangladesh 108 th,
quality of mathematics and science education in Bangladesh 118th, quality of the management
schools 101th and local availability of research and training 119th place in the world. Global
Information Technology Report (GITR) 2010 has ranked Bangladesh‟s capacity for
innovation at 123rd and availability of the latest technology at 109th place. Collaboration
between industry and research institutions is in the embryonic stage which GITR 2010 ranks
as 125th in the world, whilst quality of the scientific research institutions has been ranked at
108th place in the world.

In the last point referring to the discussion about the role of protectionism in economic
development, one sees that both cases are based on state activities to protect the sector of
pharmaceutical production from foreign influences. The regulations for banning foreign firms
from the domestic market and prohibiting the import of drugs had been the initial points for
the emergence and the success of the domestic pharmaceutical industries in both countries.
This protection created the safe haven for the entrepreneurs to get over the market and to
acquire the resources and capabilities needed to address the domestic demand, grow in the
national market and spread into the international market.

Implications for further research

The cases show that institutions and policies are not casually linked and that their positions in
proportion to the emergence of an industry are quite a complex issue. Taking a look to the
whole picture the process seems to be a co-evolutionary space consisted of entrepreneurs,
institutions and technology. Analysing the central initial points in the cases, we can postulate
that the entrepreneur kicks off the process of development of the industry. Even in insufficient
institutional environments entrepreneurs can go through that process if the profit perspective
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dominates their investment and business scenarios. This is possible if the addressed market
has potential for mass consumption, giving the entrepreneurs enough space for rental
investments.

Further research is needed to understand the implications of the entrepreneurial perspectives
more deeply and to understand how they are learned to acquire the needed capabilities.
Especially in the Syrian case the existing data and information is insufficient to answer the
raised question completely.
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